Ποια είναι η τιμή για CARsgen Therapeutics Holdings Limited (2171)

Η τιμή για CARsgen Therapeutics Holdings Limited (2171) είναι $1.72

Ποια είναι η κεφαλαιοποίηση αγοράς για CARsgen Therapeutics Holdings Limited (2171)

Η κεφαλαιοποίηση αγοράς για CARsgen Therapeutics Holdings Limited (2171) είναι $981.92M

CARsgen Therapeutics Holdings Limited (2171) Τιμή και Κεφαλαιοποίηση Αγοράς

CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.

Η τιμή για 2171	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$9,237.58 $981.92M	NVDA	$5.264T	+535,981.63%
$8,250.28 $981.92M	AAPL	$4.701T	+478,686.28%
$7,330.54 $981.92M	GOOG	$4.177T	+425,311.19%
$6,699.17 $981.92M	MSFT	$3.817T	+388,670.90%
$5,030.14 $981.92M	AMZN	$2.866T	+291,812.83%

Η τιμή για 2171

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$9,237.58 $981.92M